Development of Transgender and Gender-Diverse CanScreen: A Novel Clinical Decision Support Tool for Cancer Risk Assessment and Management in Trans and Gender-Diverse Individuals
JCO Clinical Cancer Informatics · 2026-10 · 10 (4)
DOI: 10.1200/cci-26-00170 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2026-10. Verfasst von Joyce Gong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Data Science, Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Decision Support Systems, Clinical, Neoplasms, Transgender Persons. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
Purpose
Transgender and gender-diverse (TGD) individuals face significant disparities in health care, including in cancer risk assessment and screening, because of limited population-based research on cancer risks and discrepancies in evidence-based screening guidelines. This study introduces TGD CanScreen, a clinical decision support tool designed to provide personalized cancer risk assessments and screening information for TGD individuals and their providers using current guidelines and primary literature to mitigate existing challenges.
Methods
This web-based application uses a React frontend to collect user inputs such as sex assigned at birth, gender, gender-affirming hormone usage, surgical history, and family history of cancer or inherited cancer risks. These inputs are processed by a Spring Boot backend, which queries an structured query language database to generate personalized health messages based on predefined algorithms. The database was developed based on review of the primary literature and available professional guidelines.
Results
The resulting health messages offer insights into cancer risks and screening recommendations tailored to the patient's inputs. By leveraging web development and a robust data management system, TGD CanScreen clarifies cancer risks and enhances the accessibility of relevant cancer screening guidelines, aiming to promote informed decision making and improved health care outcomes for the TGD community.
Conclusion
TGD CanScreen represents a significant advancement in providing inclusive and precise health care services, addressing a critical gap in current medical practices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
- Brown University, Providence, RI.
- Intermountain Health, Salt Lake City, UT.
- University of Michigan, Michigan Medicine Rogel Cancer Center, Ann Arbor, MI.
- Cancer Genetics Services, University of California, Los Angeles (UCLA), Los Angeles, CA.
- Division of Cancer Genetics & Prevention, Dana-Farber Cancer Institute, Boston, MA.
ORCID-Profile: Joyce Gong, Bailey B Hulswit, Minyu Denise Ma, Danielle Braun
Zitieren
APA
Gong, J., Vickrey, A. I., Hulswit, B. B., Ramesh, N., Denise Ma, M., & Braun, D. (2026). Development of Transgender and Gender-Diverse CanScreen: A Novel Clinical Decision Support Tool for Cancer Risk Assessment and Management in Trans and Gender-Diverse Individuals. JCO Clinical Cancer Informatics, 10(4). https://doi.org/10.1200/cci-26-00170
Vancouver
Gong J, Vickrey AI, Hulswit BB, Ramesh N, Denise Ma M, Braun D. Development of Transgender and Gender-Diverse CanScreen: A Novel Clinical Decision Support Tool for Cancer Risk Assessment and Management in Trans and Gender-Diverse Individuals. JCO Clinical Cancer Informatics. 2026;10(4). doi:10.1200/cci-26-00170
BibTeX
@article{Gong2026,
author = {Gong, Joyce and Vickrey, Anna I and Hulswit, Bailey B and Ramesh, Nikhila and Denise Ma, Minyu and Braun, Danielle},
title = {Development of Transgender and Gender-Diverse CanScreen: A Novel Clinical Decision Support Tool for Cancer Risk Assessment and Management in Trans and Gender-Diverse Individuals},
journal = {JCO Clinical Cancer Informatics},
year = {2026},
volume = {10},
number = {4},
doi = {10.1200/cci-26-00170}
}
EUVIMED